In such a setting, patients whose cancer cells express PD-L1 could benefit from therapy approaches that target the immune suppressive activities of immune checkpoints such as PD-1 and CTLA-4, alongside with inhibition of the cell-autonomous functions of PD-L1, which would allow for a stronger therapeutic impact in TNBC. This evidence concerns the gene CTLA4 and cancer.